Lipid lowering (% change) | |||||
---|---|---|---|---|---|
Treatment | Chol | Trig | HDL | Reduction in CHD end point | |
Baseline mean cholesterol 4.5–6.5 mmol/l. | |||||
Coronary Drug Project (1975)w33 | Nicotinic acid | −10 | −26 | ↓23% | |
Clofibrate | −7 | −22 | ↓23% | ||
Stockholm Ischaemic Heart Disease Secondary Prevention Study (1988)w34 | Clofibrate + nicotinic acid | −13 | −19 | ↓36% | |
Veterans Affairs Cooperative Studies Program: High Density Lipoprotein Cholesterol Intervention Trial (VA-HIT) (1999)w35 | Gemfibrozil | −4 | −31 | +6 | ↓22% |
Bezafibrate Infarction Prevention (BIP) Study (2000)w36 | Bezafibrate | −4 | −21 | +18 | NS (↓40% only in Trig >2.3) |